Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2 - PubMed

Affiliations

Affiliations

• 1 CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China.
• 2 CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China; University of Chinese Academy of Sciences, Beijing, China.
• 3 Department of Laboratory Medicine, The People's Hospital of Suzhou New District, Suzhou, China.
• 4 Acrobiosystems Inc, Beijing, China.
• 5 CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China. Electronic address: szliyong@sibet.ac.cn.
• 6 CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China. Electronic address: weiss@sibet.ac.cn.

• PMID: 33191178
• PMCID: PMC7608017
• DOI: 10.1016/j.intimp.2020.107172

Item in Clipboard

Shuangshi Wei  et al. Int Immunopharmacol . 2021 Jan .

Free PMC article

Authors

Affiliations

• 1 CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China.
• 2 CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China; University of Chinese Academy of Sciences, Beijing, China.
• 3 Department of Laboratory Medicine, The People's Hospital of Suzhou New District, Suzhou, China.
• 4 Acrobiosystems Inc, Beijing, China.
• 5 CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China. Electronic address: szliyong@sibet.ac.cn.
• 6 CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China. Electronic address: weiss@sibet.ac.cn.

• PMID: 33191178
• PMCID: PMC7608017
• DOI: 10.1016/j.intimp.2020.107172

Item in Clipboard

Abstract

The SARS-CoV-2 virus is still spreading worldwide, and there is an urgent need to effectively prevent and control this pandemic. This study evaluated the potential efficacy of Egg Yolk Antibodies (IgY) as a neutralizing agent against the SARS-CoV-2. We investigated the neutralizing effect of anti-spike-S1 IgYs on the SARS-CoV-2 pseudovirus, as well as its inhibitory effect on the binding of the coronavirus spike protein mutants to human ACE2. Our results show that the anti-Spike-S1 IgYs showed significant neutralizing potency against SARS-CoV-2 pseudovirus, various spike protein mutants, and even SARS-CoV in vitro. It might be a feasible tool for the prevention and control of ongoing COVID-19.

Keywords: Chicken Egg Yolk Antibodies; IgY; Neutralizing agent; SARS-CoV-2; Spike protein variants.

Copyright © 2020 Elsevier B.V. All rights reserved.

Figures

Luminescence inhibition rate curve of…

Luminescence inhibition rate curve of the anti-(SARS-Cov-2) IgY (blue) and normal (control) IgY…

Luminescence inhibition rate curve of the anti-(SARS-Cov-2) IgY (blue) and normal (control) IgY (red) from the pseudovirus neutralization assay. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Competitive inhibition of the eight…

Competitive inhibition of the eight coronavirus spike protein mutants as determined by competitive…

Competitive inhibition of the eight coronavirus spike protein mutants as determined by competitive ELISA.

Similar articles

• Immunoglobulin yolk targeting spike 1, receptor binding domain of spike glycoprotein and nucleocapsid of SARS-CoV-2 blocking RBD-ACE2 binding interaction.

  Eka Saputri M, Aisyah Rahmalia Effendi S, Nadila R, Azzam Fajar S, Damajanti Soejoedono R, Handharyani E, Nadia Poetri O. Eka Saputri M, et al. Int Immunopharmacol. 2022 Nov;112:109280. doi: 10.1016/j.intimp.2022.109280. Epub 2022 Sep 28. Int Immunopharmacol. 2022. PMID: 36183680 Free PMC article.

• Mutations in spike protein and allele variations in ACE2 impact targeted therapy strategies against SARS-CoV-2.

  Shu CJ, Huang X, Tang HH, Mo DD, Zhou JW, Deng C. Shu CJ, et al. Zool Res. 2021 Mar 18;42(2):170-181. doi: 10.24272/j.issn.2095-8137.2020.301. Zool Res. 2021. PMID: 33738989 Free PMC article.

• Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2.

  Passariello M, Gentile C, Ferrucci V, Sasso E, Vetrei C, Fusco G, Viscardi M, Brandi S, Cerino P, Zambrano N, Zollo M, De Lorenzo C. Passariello M, et al. Sci Rep. 2021 May 26;11(1):11046. doi: 10.1038/s41598-021-90348-7. Sci Rep. 2021. PMID: 34040046 Free PMC article.

• Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker.

  Bao L, Zhang C, Lyu J, Yi P, Shen X, Tang B, Zhao H, Ren B, Kuang Y, Zhou L, Li Y. Bao L, et al. J Appl Microbiol. 2022 Mar;132(3):2421-2430. doi: 10.1111/jam.15340. Epub 2021 Nov 3. J Appl Microbiol. 2022. PMID: 34706134 Free PMC article.

• Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.

  Li J, Wang P, Tracey KJ, Wang H. Li J, et al. Mol Med. 2021 May 22;27(1):49. doi: 10.1186/s10020-021-00313-3. Mol Med. 2021. PMID: 34022793 Free PMC article.

Cited by

• SARS-CoV-2-specific immunoglobulin Y antibodies are protective in infected mice.

  El-Kafrawy SA, Odle A, Abbas AT, Hassan AM, Abdel-Dayem UA, Qureshi AK, Wong LR, Zheng J, Meyerholz DK, Perlman S, Zumla A, Azhar EI. El-Kafrawy SA, et al. PLoS Pathog. 2022 Sep 19;18(9):e1010782. doi: 10.1371/journal.ppat.1010782. eCollection 2022 Sep. PLoS Pathog. 2022. PMID: 36121829 Free PMC article.

• Development of a Monoclonal scFv against Cytotoxin to Neutralize Cytolytic Activity Induced by Naja atra Venom on Myoblast C2C12 Cells.

  Liu CC, Wu CJ, Chou TY, Liaw GW, Hsiao YC, Chu LJ, Lee CH, Wang PJ, Hsieh CH, Chen CK, Yu JS. Liu CC, et al. Toxins (Basel). 2022 Jul 4;14(7):459. doi: 10.3390/toxins14070459. Toxins (Basel). 2022. PMID: 35878197 Free PMC article.

• Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review.

  Azali MA, Mohamed S, Harun A, Hussain FA, Shamsuddin S, Johan MF. Azali MA, et al. J Genet Eng Biotechnol. 2022 Jul 6;20(1):98. doi: 10.1186/s43141-022-00368-7. J Genet Eng Biotechnol. 2022. PMID: 35792966 Free PMC article. Review.

• A unique antigen against SARS-CoV-2, Acinetobacter baumannii, and Pseudomonas aeruginosa.

  Rahbar MR, Mubarak SMH, Hessami A, Khalesi B, Pourzardosht N, Khalili S, Zanoos KA, Jahangiri A. Rahbar MR, et al. Sci Rep. 2022 Jun 27;12(1):10852. doi: 10.1038/s41598-022-14877-5. Sci Rep. 2022. PMID: 35760825 Free PMC article.

• Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19.

  Frumkin LR, Lucas M, Scribner CL, Ortega-Heinly N, Rogers J, Yin G, Hallam TJ, Yam A, Bedard K, Begley R, Cohen CA, Badger CV, Abbasi SA, Dye JM, McMillan B, Wallach M, Bricker TL, Joshi A, Boon ACM, Pokhrel S, Kraemer BR, Lee L, Kargotich S, Agochiya M, John TS, Mochly-Rosen D. Frumkin LR, et al. Front Immunol. 2022 Jun 1;13:899617. doi: 10.3389/fimmu.2022.899617. eCollection 2022. Front Immunol. 2022. PMID: 35720389 Free PMC article. Clinical Trial.

References

1. 1. Zhou P., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. - PMC - PubMed
2. 1. Yan R., et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–1448. - PMC - PubMed
3. 1. Brouwer P.J.M., et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020 - PMC - PubMed
4. 1. Cao X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 2020;20:269–270. - PMC - PubMed
5. 1. Klemperer F. Uber natirliche Immunitat und ihre Verwertung fur die Immunisierungs-therapie. Arch. Expl. Pathol. Pharmakol. 1893;31:356–382.